These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 11161227)

  • 1. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
    Jonasch E; Haluska FG
    Oncologist; 2001; 6(1):34-55. PubMed ID: 11161227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy: the interferon-alpha experience.
    Kirkwood J
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):18-26. PubMed ID: 12068384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferons in the therapy of solid tumors].
    Tomao S; Mozzicafreddo A; Raffaele M; Romiti A; Papò MA; Campisi C
    Clin Ter; 1995; 146(8-9):491-502. PubMed ID: 8536432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interferons and hematology].
    Lacotte-Thierry L; Guilhot F
    Rev Med Interne; 2002 Nov; 23 Suppl 4():481s-488s. PubMed ID: 12481403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status of interferon therapy].
    Dittrich C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy.
    Jakschies D; Hochkeppel H; Horisberger M; Deicher H; von Wussow P
    J Biol Response Mod; 1990 Jun; 9(3):305-12. PubMed ID: 2380745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferons. Treatment of malignant hemopathies with interferons].
    Guilhot F; Sadoun A; Delwail V
    Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alfa-2a.
    Williams CD; Linch DC
    Br J Hosp Med; 1997 May 7-20; 57(9):436-9. PubMed ID: 9274677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotherapy with interferon--1988.
    Figlin RA
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferons in the treatment of hematological diseases].
    Jantunen E; Nousiainen T
    Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferons in oncology.
    Woll PJ; Pettengell R
    Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of hypothyroidism induced by interferon therapy for renal cell carcinoma].
    Fujita T; Honda N; Baba S
    Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):583-5. PubMed ID: 11517570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
    Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic Kaposi's sarcoma: low-dose interferon alfa treatment.
    Tur E; Brenner S
    Dermatology; 1998; 197(1):37-42. PubMed ID: 9693183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical application of the interferons: a review. NSW Therapeutic Assessment Group.
    Stuart-Harris RC; Lauchlan R; Day R
    Med J Aust; 1992 Jun; 156(12):869-72. PubMed ID: 1376397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment of combined interferon-alpha and hydroxycarbamide for chronic myelogenous leukemia following therapy for malignant lymphoma].
    Hasegawa A; Ninomiya H; Yanagisawa K; Takada K; Hasegawa H; Hato T; Yasukawa M; Fujita S
    Rinsho Ketsueki; 1996 Sep; 37(9):853-7. PubMed ID: 8914475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.